-

Plated™ Skin Science launches a revolutionary new post-procedure product, CALM, powered by Renewosome™ technology to enhance overall procedural outcomes

Rion Aesthetics launches CALM, a new post-procedure product in its ( plated )™ Skin Science collection, uniquely formulated with the power of platelet-derived Renewosome™ technology to enhance the overall patient experience

ROCHESTER, Minn.--(BUSINESS WIRE)--RION AESTHETICS, a leading regenerative aesthetics company, has announced the launch of a revolutionary new post-procedure product in the ( plated )™ Skin Science collection, CALM. As the only skincare product with RenewosomeTM technology, CALM was designed to complement post-procedure recovery and support the overall patient experience in prestigious aesthetic practices.

“We are ecstatic to offer CALM to forward-thinking aesthetic practices around the country,” stated Alisa Lask, MBA, CEO of RION AESTHETICS. “The power of the platelet-derived RenewosomeTM technology supports a new approach to post-procedure recovery while enhancing the overall patient experience in our partners’ practices.”

CALM is designed with a unique combination of ingredients to support post-procedure care and recovery and to enhance overall outcomes. The launch is supported by the Platelets on Post Procedure Skin (POPPS) Study, using CALM following CO2 laser procedure.

“I am especially pleased that the Rion Aesthetics team is supporting this launch with an innovative study evaluating CALM in the post-procedure setting,” said Dr. Steve Dayan. “Post-procedure can be especially challenging for many patients, and the ability to enhance the overall treatment experience could result in improved satisfaction for key patients in my practice. I look forward to sharing the final results of the POPPS study in the near future.”

CALM is available exclusively through leading practices that have partnered with Rion Aesthetics. Interested practices can learn more about becoming a provider by reaching out to info@platedskinscience.com

For more information, please visit www.platedskinscience.com

About ( plated )TM Skin Science

( plated )TM is a cosmetic product, designed to promote beautification and reduce the appearance of a host of cosmetic skin challenges. (plated)TM is not an FDA approved drug and is not intended to treat, cure, or prevent any condition or disease.

For more information, please talk to your aesthetics provider or visit www.platedskinscience.com

To report an adverse reaction, please contact RION AESTHETICS at info@platedskinscience.com.

About RION AESTHETICS

About Rion Aesthetics

Rion Aesthetics is a regenerative aesthetics company, founded in Rochester, Minnesota, pioneering the use of platelet-derived exosome technology in investigational studies for hair restoration and facial wrinkles. Backed by over 15 years of visionary science, we aim to transform the regenerative aesthetic market to bring “beauty from within.”

From this investigational research, we also discovered the benefits of platelet extract on skin health. Through the launch of (plated)™ Skin Science, we will transform the skincare market using our revolutionary Renewosome™ Technology from platelet-extract to help rejuvenate the skin.

Follow us on social media:
Instagram: @rionaesthetics
LinkedIn: https://www.linkedin.com/company/rion-aesthetics

Related Links
https://www.rionaesthetics.com/

Contacts

More News From RION AESTHETICS

CORRECTING and REPLACING RION Launches RION Vet to Transform Animal Health with First-in-Class Biologic Therapeutic; Appoints Industry Leader Mark Herthel as CEO; Announces Series A Fulfillment

ROCHESTER, Minn.--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions. The updated release reads: RION LAUNCHES RION VET TO TRANSFORM ANIMAL HEALTH WITH FIRST-IN-CLASS BIOLOGIC THERAPEUTIC; APPOINTS INDUSTRY LEADER MARK HERTHEL AS CEO; ANNOUNCES SERIES A FULFILLMENT RION, a clinical-stage regenerative medicine company and global leader in exosome-based therapeutics, today announced the formation of RION Vet, a veterinary biotechnology compa...

RION Engages Lonza to Scale Manufacturing Exosome Based Therapeutics

ROCHESTER, Minn. & BASEL, Switzerland--(BUSINESS WIRE)--RION, a commercial and clinical-stage regenerative medicine company pioneering platelet-derived exosomes for both human and animal health applications, has announced a collaboration with Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), to provide cGMP manufacturing and technical support for commercial scale production of its Purified Exosome Product™ (PEP™) drug substance for late phase clinic...

RION Launches INTENT Biologics to Develop Late-Stage Clinical Exosome-Based Therapies in Inflammation & Immunology; Appoints Biopharma Veteran Suneet Varma as CEO

ROCHESTER, Minn.--(BUSINESS WIRE)--RION, a clinical-stage regenerative medicine company and global leader in exosome-based therapeutics, today announced the formation of INTENT Biologics, a new independent biotechnology company focused exclusively on developing first-in-class exosome therapies for Inflammation & Immunology (I&I). INTENT Biologics launches with exclusive, perpetual worldwide rights to RION’s Purified Exosome Product (PEP™) biologic platform in I&I and will advance PE...
Back to Newsroom